GlassScriptPhysician profile
Paul L Lograno
NPI 1871577080
$602.64
in general payments reported to CMS, 2019-2025
12 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.23 · 2020: $18.15 · 2021: $93.28 · 2022: $50.99 · 2023: $86.92 · 2024: $60.64 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $112.99 | 2022-2025 | |
| Amgen INC. | $77.85 | 2020-2025 | Evenity, Prolia, Prolia |
| Aspira Women'S Health INC | $65.42 | 2021 | |
| Astellas Pharma US INC | $58.60 | 2023-2024 | Veozah |
| Pfizer INC. | $50.00 | 2025 | |
| Daiichi Sankyo INC. | $47.61 | 2024-2025 | Injectafer |
| Organon LLC | $46.16 | 2023 | Nexplanon |
| Hologic Sales and Service, LLC | $44.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.05 | 2025 | |
| Thd America, INC. | $28.42 | 2025 | |
| Coopersurgical, INC. | $27.86 | 2021 | |
| Shield Therapeutics INC | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lograno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.